



Name: Thomas F Glembocki
Date of Birth: 06-Nov-1946
Gender Identity: Male

Results

Order: LIPID PANEL (80061)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	12/23/2011	194.00	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	12/23/2011	103.00	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	12/23/2011	21.00	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL Cholesterol Calc	12/23/2011	126.00	mg/dL	0-99	Raleigh Medical Group, P.A.
HDL Cholesterol	12/23/2011	47.00	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	12/23/2011	6.90	x10E3/uL	4.0-10.5	Raleigh Medical Group, P.A.
RBC	12/23/2011	4.69	x10E6/uL	4.10-5.60	Raleigh Medical Group, P.A.
Hemoglobin	12/23/2011	14.20	g/dL	12.5-17.0	Raleigh Medical Group, P.A.
Hematocrit	12/23/2011	41.90	%	36.0-50.0	Raleigh Medical Group, P.A.
MCV	12/23/2011	89.00	fL	80-98	Raleigh Medical Group, P.A.
MCH	12/23/2011	30.30	pg	27.0-34.0	Raleigh Medical Group, P.A.
MCHC	12/23/2011	33.90	g/dL	32.0-36.0	Raleigh Medical Group, P.A.
RDW	12/23/2011	13.00	%	11.7-15.0	Raleigh Medical Group, P.A.
Platelets	12/23/2011	240.00	x10E3/uL	140-415	Raleigh Medical Group, P.A.
Neutrophils	12/23/2011	55.00	%	40-74	Raleigh Medical Group, P.A.
Lymphs	12/23/2011	32.00	%	14-46	Raleigh Medical Group, P.A.
Monocytes	12/23/2011	10.00	%	4-13	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Eos	12/23/2011	2.00	%	0-7	Raleigh Medical Group, P.A.
Basos	12/23/2011	1.00	%	0-3	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	12/23/2011	3.80	x10E3/uL	1.8-7.8	Raleigh Medical Group, P.A.
Lymphs (Absolute)	12/23/2011	2.20	x10E3/uL	0.7-4.5	Raleigh Medical Group, P.A.
Monocytes(Absolute)	12/23/2011	0.70	x10E3/uL	0.1-1.0	Raleigh Medical Group, P.A.
Eos (Absolute)	12/23/2011	0.10	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	12/23/2011	0.10	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	12/23/2011	0.00	%	0-2	Raleigh Medical Group, P.A.
Immature Grans (Abs)	12/23/2011	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Comprehensive Metabolic Panel with eGFR (80053)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose, Serum	12/23/2011	89.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	12/23/2011	13.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	12/23/2011	0.97	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
BUN/Creatinine Ratio	12/23/2011	13.00		10-22	Raleigh Medical Group, P.A.
Potassium, Serum	12/23/2011	3.80	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	12/23/2011	98.00	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	12/23/2011	25.00	mmol/L	20-32	Raleigh Medical Group, P.A.
Calcium, Serum	12/23/2011	9.00	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	12/23/2011	6.90	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	12/23/2011	4.40	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	12/23/2011	2.50	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
Sodium, Serum	12/23/2011	139.00	mmol/L	134-144	Raleigh Medical Group, P.A.

Notes:

Please note reference interval change

Please note reference interval change

A/G Ratio	12/23/2011	1.80		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	12/23/2011	0.50	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	12/23/2011	70.00	IU/L	25-160	Raleigh Medical Group, P.A.
AST (SGOT)	12/23/2011	19.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	12/23/2011	19.00	IU/L	0-55	Raleigh Medical Group, P.A.

Order: Prostate-Specific Ag, Serum

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	12/28/2011	0.80	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should

decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial

PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory

PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

interchangeably. Results cannot be interpreted as absolute evidence

of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should

decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial

PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory

PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

interchangeably. Results cannot be interpreted as absolute evidence

of the presence or absence of malignant disease.

Order: Verbal Add-on

Notes:

PATIENT WAS FASTING

PERFORMED BY: BN LabCorp Burlington

1447 York Court

Burlington NC 272153361

8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Verbal Add-on	12/28/2011	Comment			Raleigh Medical Group, P.A.

Notes:

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

This report has been generated by your request for additional testing.
The additional request may have required some testing to be repeated.
Because of analytic variability, the results may not correspond exactly to the previous report. Interpret these results appropriately.

This report has been generated by your request for additional testing.
The additional request may have required some testing to be repeated.
Because of analytic variability, the results may not correspond exactly to the previous report. Interpret these results appropriately.

Order: Written Authorization

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Written Authorization	12/28/2011	Comment			Raleigh Medical Group, P.A.

Notes:

Written Authorization Received.
Authorization received from DEREK SCHRODER 12-28-2011
Logged by Latosha Bayron

Written Authorization Received.
Authorization received from DEREK SCHRODER 12-28-2011
Logged by Latosha Bayron

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	1/19/2013	6.40	x10E3/uL	4.0-10.5	Raleigh Medical Group, P.A.
RBC	1/19/2013	4.76	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	1/19/2013	14.40	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	1/19/2013	42.20	%	37.5-51.0	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
MCV	1/19/2013	89.00	fL	79-97	Raleigh Medical Group, P.A.
MCH	1/19/2013	30.30	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	1/19/2013	34.10	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	1/19/2013	13.20	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	1/19/2013	270.00	x10E3/uL	140-415	Raleigh Medical Group, P.A.
Neutrophils	1/19/2013	56.00	%	40-74	Raleigh Medical Group, P.A.
Lymphs	1/19/2013	31.00	%	14-46	Raleigh Medical Group, P.A.
Monocytes	1/19/2013	9.00	%	4-13	Raleigh Medical Group, P.A.
Eos	1/19/2013	3.00	%	0-7	Raleigh Medical Group, P.A.
Basos	1/19/2013	1.00	%	0-3	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	1/19/2013	3.60	x10E3/uL	1.8-7.8	Raleigh Medical Group, P.A.
Lymphs (Absolute)	1/19/2013	2.00	x10E3/uL	0.7-4.5	Raleigh Medical Group, P.A.
Monocytes(Absolute)	1/19/2013	0.60	x10E3/uL	0.1-1.0	Raleigh Medical Group, P.A.
Eos (Absolute)	1/19/2013	0.20	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	1/19/2013	0.10	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	1/19/2013	0.00	%	0-2	Raleigh Medical Group, P.A.
Immature Grans (Abs)	1/19/2013	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Comprehensive Metabolic Panel with eGFR (80053)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose, Serum	1/19/2013	88.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	1/19/2013	13.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	1/19/2013	1.08	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	1/19/2013	12.00		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	1/19/2013	139.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	1/19/2013	4.10	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	1/19/2013	100.00	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	1/19/2013	25.00	mmol/L	20-32	Raleigh Medical Group, P.A.
Calcium, Serum	1/19/2013	9.20	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	1/19/2013	6.70	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	1/19/2013	4.30	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	1/19/2013	2.40	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	1/19/2013	1.80		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	1/19/2013	0.50	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	1/19/2013	65.00	IU/L	25-160	Raleigh Medical Group, P.A.
AST (SGOT)	1/19/2013	14.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	1/19/2013	20.00	IU/L	0-44	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	1/19/2013	195.00	mg/dL	100-199	Raleigh Medical Group, P.A.
VLDL Cholesterol Calc	1/19/2013	34.00	mg/dL	5-40	Raleigh Medical Group, P.A.
Triglycerides	1/19/2013	170.00	mg/dL	0-149	Raleigh Medical Group, P.A.
LDL Cholesterol Calc	1/19/2013	123.00	mg/dL	0-99	Raleigh Medical Group, P.A.
LDL/HDL Ratio	1/19/2013	3.20	ratio units	0.0-3.6	Raleigh Medical Group, P.A.
HDL Cholesterol	1/19/2013	38.00	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Order: PSA Serum 010322 (84153)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	1/19/2013	0.70	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should

decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial

PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory

PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

interchangeably. Results cannot be interpreted as absolute evidence

of the presence or absence of malignant disease.

Order: METABOLIC PANEL, BASIC (80048)

Notes:

PERFORMED BY: 01 LabCorp Burlington

1447 York Court

Burlington NC 272153361

8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose, Serum	3/2/2013	88.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	3/2/2013	17.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	3/2/2013	0.96	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	3/2/2013	18.00		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	3/2/2013	138.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	3/2/2013	4.10	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	3/2/2013	97.00	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	3/2/2013	27.00	mmol/L	20-32	Raleigh Medical Group, P.A.
Calcium, Serum	3/2/2013	9.60	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.

Order: TISSUE EXAM BY PATHOLOGIST, LVL IV (88305)

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
TISSUE EXAM BY PATHOLOGIST, LVL IV	3/8/2013	see Pathology report			Raleigh Medical Group, P.A.

Order: TISSUE EXAM BY PATHOLOGIST, LVL IV (88305)

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
TISSUE EXAM BY PATHOLOGIST, LVL IV	3/8/2013	see Pathology report			Raleigh Medical Group, P.A.

Order: PSA, TOTAL 010322 (84153)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	3/15/2014	1.00	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: Lipid Panel (LDL:HDL ratio) (80061)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	3/15/2014	176.00	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	3/15/2014	112.00	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	3/15/2014	22.00	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL/HDL Ratio	3/15/2014	3.10	ratio units	0.0-3.6	Raleigh Medical Group, P.A.
HDL Cholesterol	3/15/2014	38.00	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

LDL Cholesterol Calc	3/15/2014	116.00	mg/dL	0-99	Raleigh Medical Group, P.A.
----------------------	-----------	--------	-------	------	-----------------------------

Order: Metabolic Panel, Comprehensive (80053)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose, Serum	3/15/2014	87.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	3/15/2014	12.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	3/15/2014	1.03	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	3/15/2014	12.00		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	3/15/2014	138.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	3/15/2014	4.40	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride, Serum	3/15/2014	98.00	mmol/L	97-108	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	3/15/2014	28.00	mmol/L	19-28	Raleigh Medical Group, P.A.
Calcium, Serum	3/15/2014	9.60	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	3/15/2014	6.90	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	3/15/2014	4.40	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	3/15/2014	2.50	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	3/15/2014	1.80		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	3/15/2014	0.70	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	3/15/2014	61.00	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	3/15/2014	16.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	3/15/2014	21.00	IU/L	0-44	Raleigh Medical Group, P.A.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court

Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	3/15/2014	5.60	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	3/15/2014	4.73	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	3/15/2014	14.40	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	3/15/2014	42.40	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	3/15/2014	90.00	fL	79-97	Raleigh Medical Group, P.A.
MCH	3/15/2014	30.40	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	3/15/2014	34.00	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	3/15/2014	13.20	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	3/15/2014	237.00	x10E3/uL	155-379	Raleigh Medical Group, P.A.
Neutrophils	3/15/2014	55.00	%	40-74	Raleigh Medical Group, P.A.
Lymphs	3/15/2014	33.00	%	14-46	Raleigh Medical Group, P.A.
Monocytes	3/15/2014	9.00	%	4-12	Raleigh Medical Group, P.A.
Eos	3/15/2014	2.00	%	0-5	Raleigh Medical Group, P.A.
Basos	3/15/2014	1.00	%	0-3	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	3/15/2014	3.10	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	3/15/2014	1.80	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	3/15/2014	0.50	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	3/15/2014	0.10	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	3/15/2014	0.00	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	3/15/2014	0.00	%	0-2	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Immature Grans (Abs)	3/15/2014	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: PSA - TOTAL 010322 (84153)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	3/26/2015	0.70	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: LIPID PANEL (80061)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	3/26/2015	161.00	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	3/26/2015	85.00	mg/dL	0-149	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	3/26/2015	17.00	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL Cholesterol Calc	3/26/2015	107.00	mg/dL	0-99	Raleigh Medical Group, P.A.
HDL Cholesterol	3/26/2015	37.00	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

Order: Comprehensive Metabolic Panel with eGFR (80053)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose, Serum	3/26/2015	93.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	3/26/2015	10.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine, Serum	3/26/2015	1.06	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
Sodium, Serum	3/26/2015	135.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	3/26/2015	4.10	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	3/26/2015	25.00	mmol/L	18-29	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Calcium, Serum	3/26/2015	9.50	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	3/26/2015	6.50	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	3/26/2015	4.30	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	3/26/2015	2.20	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	3/26/2015	2.00		1.1-2.5	Raleigh Medical Group, P.A.
Bilirubin, Total	3/26/2015	0.60	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	3/26/2015	9.00		10-22	Raleigh Medical Group, P.A.
Chloride, Serum	3/26/2015	93.00	mmol/L	97-108	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	3/26/2015	61.00	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	3/26/2015	15.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	3/26/2015	19.00	IU/L	0-44	Raleigh Medical Group, P.A.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PERFORMED BY: 01 LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	3/26/2015	5.60	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	3/26/2015	4.71	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	3/26/2015	14.10	g/dL	12.6-17.7	Raleigh Medical Group, P.A.
Hematocrit	3/26/2015	40.50	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	3/26/2015	86.00	fL	79-97	Raleigh Medical Group, P.A.
MCH	3/26/2015	29.90	pg	26.6-33.0	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
MCHC	3/26/2015	34.80	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	3/26/2015	12.60	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	3/26/2015	300.00	x10E3/uL	150-379	Raleigh Medical Group, P.A.
Neutrophils	3/26/2015	49.00	%		Raleigh Medical Group, P.A.
Lymphs	3/26/2015	36.00	%		Raleigh Medical Group, P.A.
Monocytes	3/26/2015	13.00	%		Raleigh Medical Group, P.A.
Eos	3/26/2015	1.00	%		Raleigh Medical Group, P.A.
Basos	3/26/2015	1.00	%		Raleigh Medical Group, P.A.
Neutrophils (Absolute)	3/26/2015	2.80	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	3/26/2015	2.00	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	3/26/2015	0.70	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	3/26/2015	0.10	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	3/26/2015	0.00	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	3/26/2015	0.00	%		Raleigh Medical Group, P.A.
Immature Grans (Abs)	3/26/2015	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Metabolic Panel (14), Comprehensive w/o GFR (80053)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose, Serum	4/1/2016	88.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	4/1/2016	11.00	mg/dL	8-27	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Creatinine, Serum	4/1/2016	1.13	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	4/1/2016	10.00		10-22	Raleigh Medical Group, P.A.
Sodium, Serum	4/1/2016	135.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium, Serum	4/1/2016	4.70	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	4/1/2016	25.00	mmol/L	18-29	Raleigh Medical Group, P.A.
Calcium, Serum	4/1/2016	9.80	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total, Serum	4/1/2016	7.10	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin, Serum	4/1/2016	4.60	g/dL	3.6-4.8	Raleigh Medical Group, P.A.
Globulin, Total	4/1/2016	2.50	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	4/1/2016	1.80		1.1-2.5	Raleigh Medical Group, P.A.
Chloride, Serum	4/1/2016	96.00	mmol/L	97-108	Raleigh Medical Group, P.A.
Bilirubin, Total	4/1/2016	0.80	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase, S	4/1/2016	60.00	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	4/1/2016	23.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	4/1/2016	21.00	IU/L	0-44	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	4/1/2016	166.00	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	4/1/2016	96.00	mg/dL	0-149	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
VLDL Cholesterol Cal	4/1/2016	19.00	mg/dL	5-40	Raleigh Medical Group, P.A.
HDL Cholesterol	4/1/2016	43.00	mg/dL	>39	Raleigh Medical Group, P.A.

Notes:

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.

LDL/HDL Ratio	4/1/2016	2.40	ratio units	0.0-3.6	Raleigh Medical Group, P.A.
---------------	----------	------	----------------	---------	--------------------------------

Notes:

LDL/HDL Ratio		
	Men	Women
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL/HDL Ratio		
	Men	Women
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL Cholesterol Calc	4/1/2016	104.00	mg/dL	0-99	Raleigh Medical Group, P.A.
-------------------------	----------	--------	-------	------	--------------------------------

Order: PSA, TOTAL 010322 (84153)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	4/1/2016	1.20	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	4/1/2016	5.40	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	4/1/2016	4.69	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	4/1/2016	14.80	g/dL	12.6-17.7	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Hematocrit	4/1/2016	42.80	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	4/1/2016	91.00	fL	79-97	Raleigh Medical Group, P.A.
MCH	4/1/2016	31.60	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	4/1/2016	34.60	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	4/1/2016	13.60	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	4/1/2016	252.00	x10E3/uL	150-379	Raleigh Medical Group, P.A.
Neutrophils	4/1/2016	54.00	%		Raleigh Medical Group, P.A.
Lymphs	4/1/2016	31.00	%		Raleigh Medical Group, P.A.
Monocytes	4/1/2016	13.00	%		Raleigh Medical Group, P.A.
Eos	4/1/2016	2.00	%		Raleigh Medical Group, P.A.
Basos	4/1/2016	0.00	%		Raleigh Medical Group, P.A.
Neutrophils (Absolute)	4/1/2016	2.90	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	4/1/2016	1.70	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	4/1/2016	0.70	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	4/1/2016	0.10	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	4/1/2016	0.00	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	4/1/2016	0.00	%		Raleigh Medical Group, P.A.
Immature Grans (Abs)	4/1/2016	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court

Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	10/17/2018	6.50	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	10/17/2018	4.58	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	10/17/2018	13.90	g/dL	13.0-17.7	Raleigh Medical Group, P.A.
Hematocrit	10/17/2018	40.70	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	10/17/2018	89.00	fL	79-97	Raleigh Medical Group, P.A.
MCH	10/17/2018	30.30	pg	26.6-33.0	Raleigh Medical Group, P.A.
MCHC	10/17/2018	34.20	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	10/17/2018	13.40	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	10/17/2018	245.00	x10E3/uL	150-379	Raleigh Medical Group, P.A.
Neutrophils	10/17/2018	53.00	%	Not Estab.	Raleigh Medical Group, P.A.
Lymphs	10/17/2018	33.00	%	Not Estab.	Raleigh Medical Group, P.A.
Monocytes	10/17/2018	11.00	%	Not Estab.	Raleigh Medical Group, P.A.
Eos	10/17/2018	2.00	%	Not Estab.	Raleigh Medical Group, P.A.
Basos	10/17/2018	1.00	%	Not Estab.	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Neutrophils (Absolute)	10/17/2018	3.50	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	10/17/2018	2.10	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	10/17/2018	0.70	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	10/17/2018	0.10	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	10/17/2018	0.00	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	10/17/2018	0.00	%	Not Estab.	Raleigh Medical Group, P.A.
Immature Grans (Abs)	10/17/2018	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	10/17/2018	158.00	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	10/17/2018	83.00	mg/dL	0-149	Raleigh Medical Group, P.A.
HDL Cholesterol	10/17/2018	39.00	mg/dL	>39	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	10/17/2018	17.00	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL/HDL Ratio	10/17/2018	2.60	ratio	0.0-3.6	Raleigh Medical Group, P.A.

Notes:

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
LDL/HDL Ratio					
Men Women					
1/2 Avg.Risk 1.0 1.5					
Avg.Risk 3.6 3.2					
2X Avg.Risk 6.2 5.0					
3X Avg.Risk 8.0 6.1					
LDL/HDL Ratio					
Men Women					
1/2 Avg.Risk 1.0 1.5					
Avg.Risk 3.6 3.2					
2X Avg.Risk 6.2 5.0					
3X Avg.Risk 8.0 6.1					
LDL Cholesterol Calc	10/17/2018	102.00	mg/dL	0-99	Raleigh Medical Group, P.A.

Order: Metabolic Panel (14), Comprehensive w/o GFR (80053)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose	10/17/2018	90.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	10/17/2018	14.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine	10/17/2018	1.08	mg/dL	0.76- 1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	10/17/2018	13.00		10-24	Raleigh Medical Group, P.A.
Potassium	10/17/2018	3.70	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	10/17/2018	25.00	mmol/L	20-29	Raleigh Medical Group, P.A.
Calcium	10/17/2018	9.90	mg/dL	8.6- 10.2	Raleigh Medical Group, P.A.
Protein, Total	10/17/2018	6.90	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin	10/17/2018	4.40	g/dL	3.5-4.8	Raleigh Medical Group, P.A.
Globulin, Total	10/17/2018	2.50	g/dL	1.5-4.5	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
A/G Ratio	10/17/2018	1.80		1.2-2.2	Raleigh Medical Group, P.A.
Bilirubin, Total	10/17/2018	0.60	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Sodium	10/17/2018	133.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Chloride	10/17/2018	93.00	mmol/L	96-106	Raleigh Medical Group, P.A.
Alkaline Phosphatase	10/17/2018	66.00	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	10/17/2018	19.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	10/17/2018	15.00	IU/L	0-44	Raleigh Medical Group, P.A.

Order: PSA (Medicare) (G0103)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	10/17/2018	0.90	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
-------------	-------------	--------------	--------------	--------------	---------------

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Order: CBC WITH DIFF/PLT COUNT/AUTOMATED (85025)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court
Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
WBC	10/22/2019	5.50	x10E3/uL	3.4-10.8	Raleigh Medical Group, P.A.
RBC	10/22/2019	4.56	x10E6/uL	4.14-5.80	Raleigh Medical Group, P.A.
Hemoglobin	10/22/2019	14.00	g/dL	13.0-17.7	Raleigh Medical Group, P.A.
Hematocrit	10/22/2019	41.10	%	37.5-51.0	Raleigh Medical Group, P.A.
MCV	10/22/2019	90.00	fL	79-97	Raleigh Medical Group, P.A.
MCH	10/22/2019	30.70	pg	26.6-33.0	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
MCHC	10/22/2019	34.10	g/dL	31.5-35.7	Raleigh Medical Group, P.A.
RDW	10/22/2019	12.40	%	12.3-15.4	Raleigh Medical Group, P.A.
Platelets	10/22/2019	213.00	x10E3/uL	150-450	Raleigh Medical Group, P.A.
Neutrophils	10/22/2019	52.00	%	Not Estab.	Raleigh Medical Group, P.A.
Lymphs	10/22/2019	34.00	%	Not Estab.	Raleigh Medical Group, P.A.
Monocytes	10/22/2019	10.00	%	Not Estab.	Raleigh Medical Group, P.A.
Eos	10/22/2019	3.00	%	Not Estab.	Raleigh Medical Group, P.A.
Basos	10/22/2019	1.00	%	Not Estab.	Raleigh Medical Group, P.A.
Neutrophils (Absolute)	10/22/2019	2.80	x10E3/uL	1.4-7.0	Raleigh Medical Group, P.A.
Lymphs (Absolute)	10/22/2019	1.90	x10E3/uL	0.7-3.1	Raleigh Medical Group, P.A.
Monocytes(Absolute)	10/22/2019	0.60	x10E3/uL	0.1-0.9	Raleigh Medical Group, P.A.
Eos (Absolute)	10/22/2019	0.20	x10E3/uL	0.0-0.4	Raleigh Medical Group, P.A.
Baso (Absolute)	10/22/2019	0.00	x10E3/uL	0.0-0.2	Raleigh Medical Group, P.A.
Immature Granulocytes	10/22/2019	0.00	%	Not Estab.	Raleigh Medical Group, P.A.

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Immature Grans (Abs)	10/22/2019	0.00	x10E3/uL	0.0-0.1	Raleigh Medical Group, P.A.

Order: Lipid Panel (LDL:HDL ratio) (80061)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court
 Burlington NC 272153361
 8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Cholesterol, Total	10/22/2019	198.00	mg/dL	100-199	Raleigh Medical Group, P.A.
Triglycerides	10/22/2019	131.00	mg/dL	0-149	Raleigh Medical Group, P.A.
HDL Cholesterol	10/22/2019	38.00	mg/dL	>39	Raleigh Medical Group, P.A.
VLDL Cholesterol Cal	10/22/2019	26.00	mg/dL	5-40	Raleigh Medical Group, P.A.
LDL/HDL Ratio	10/22/2019	3.50	ratio	0.0-3.6	Raleigh Medical Group, P.A.

Notes:

LDL/HDL Ratio		
	Men	Women
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1
LDL/HDL Ratio		
	Men	Women
1/2 Avg.Risk	1.0	1.5
Avg.Risk	3.6	3.2
2X Avg.Risk	6.2	5.0
3X Avg.Risk	8.0	6.1

LDL Cholesterol Calc	10/22/2019	134.00	mg/dL	0-99	Raleigh Medical Group, P.A.
-------------------------	------------	--------	-------	------	--------------------------------

Order: Metabolic Panel (14), Comprehensive w/o GFR (80053)

Notes:

PATIENT WAS FASTING
 PERFORMED BY: BN LabCorp Burlington
 1447 York Court

Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Glucose	10/22/2019	92.00	mg/dL	65-99	Raleigh Medical Group, P.A.
BUN	10/22/2019	14.00	mg/dL	8-27	Raleigh Medical Group, P.A.
Creatinine	10/22/2019	1.14	mg/dL	0.76-1.27	Raleigh Medical Group, P.A.
BUN/Creatinine Ratio	10/22/2019	12.00		10-24	Raleigh Medical Group, P.A.
Sodium	10/22/2019	138.00	mmol/L	134-144	Raleigh Medical Group, P.A.
Potassium	10/22/2019	4.10	mmol/L	3.5-5.2	Raleigh Medical Group, P.A.
Chloride	10/22/2019	97.00	mmol/L	96-106	Raleigh Medical Group, P.A.
Carbon Dioxide, Total	10/22/2019	25.00	mmol/L	20-29	Raleigh Medical Group, P.A.
Calcium	10/22/2019	9.60	mg/dL	8.6-10.2	Raleigh Medical Group, P.A.
Protein, Total	10/22/2019	6.70	g/dL	6.0-8.5	Raleigh Medical Group, P.A.
Albumin	10/22/2019	4.50	g/dL	3.5-4.8	Raleigh Medical Group, P.A.
Globulin, Total	10/22/2019	2.20	g/dL	1.5-4.5	Raleigh Medical Group, P.A.
A/G Ratio	10/22/2019	2.00		1.2-2.2	Raleigh Medical Group, P.A.
Bilirubin, Total	10/22/2019	0.70	mg/dL	0.0-1.2	Raleigh Medical Group, P.A.
Alkaline Phosphatase	10/22/2019	56.00	IU/L	39-117	Raleigh Medical Group, P.A.
AST (SGOT)	10/22/2019	20.00	IU/L	0-40	Raleigh Medical Group, P.A.
ALT (SGPT)	10/22/2019	19.00	IU/L	0-44	Raleigh Medical Group, P.A.

Order: PSA (Medicare) (G0103)

Notes:

PATIENT WAS FASTING
PERFORMED BY: BN LabCorp Burlington
1447 York Court

Burlington NC 272153361
8007624344

<u>Name</u>	<u>Date</u>	<u>Value</u>	<u>Units</u>	<u>Range</u>	<u>Source</u>
Prostate Specific Ag, Serum	10/22/2019	0.90	ng/mL	0.0-4.0	Raleigh Medical Group, P.A.

Notes:

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should

decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial

PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory

PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

interchangeably. Results cannot be interpreted as absolute evidence

of the presence or absence of malignant disease.

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should

decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial

PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory

PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used

interchangeably. Results cannot be interpreted as absolute evidence

of the presence or absence of malignant disease.

DISCLAIMER: This information is supplied from the patient's medical record via a patient portal. The medical provider is listed as the source. Items with a source of 'Patient-Entered' were added by the patient. This record may not be complete or up to date, and should not be used for providing medical advice. For an official copy of the individual's medical record, the patient (or custodian) must contact their medical provider.

